Intellia Therapeutics (NTLA) stock is soaring 10.84% in intraday trading, building on its pre-market momentum following the release of its impressive first-quarter 2025 financial results. The gene-editing company's performance has significantly surpassed market expectations, driving investor enthusiasm and pushing the stock to new heights.

Intellia reported a Q1 earnings per share (EPS) of $(1.10), beating the estimated $(1.27). The company's sales for the quarter reached $16.63 million, substantially outperforming the projected $11.87 million. This strong financial performance demonstrates Intellia's ability to exceed market expectations and showcases the growing potential of its gene-editing technology platform.

Adding to investor optimism, Intellia announced a robust cash position of approximately $707.1 million in cash, cash equivalents, and marketable securities at the end of Q1 2025. This substantial financial cushion is expected to fund the company's operations into the first half of 2027, providing Intellia with an extended runway to advance its pipeline and potentially bring groundbreaking gene therapies to market. The combination of strong quarterly results, a solid financial foundation, and the promise of its innovative technology has clearly resonated with investors, driving the significant rally in Intellia's stock price.